Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study
| Autor: | Fei Xu, Li Kun Chen, Yin Duo Zeng, Li Zhang, Xiao Xiao Dinglin, Ying Liang, Jun Ling Liu, Hai Liao |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty Lung Neoplasms Epidemiology medicine.drug_class Antineoplastic Agents Tyrosine-kinase inhibitor Gefitinib Internal medicine Carcinoma Non-Small-Cell Lung medicine Humans heterocyclic compounds Epidermal growth factor receptor skin and connective tissue diseases Lung cancer neoplasms Protein Kinase Inhibitors Aged Retrospective Studies biology business.industry Brain Neoplasms Standard treatment Public Health Environmental and Occupational Health Chemoradiotherapy medicine.disease respiratory tract diseases ErbB Receptors Treatment Outcome Concomitant biology.protein Disease Progression Quinazolines Female business Brain metastasis medicine.drug |
| Zdroj: | Asian Pacific journal of cancer prevention : APJCP. 13(3) |
| ISSN: | 2476-762X |
| Popis: | Background: Gefitinib, a tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR), is used both as a single drug and concurrently with whole brain radiotherapy (WBRT) the standard treatment for brain metastases (BM), and is reported to be effective in a few small studies of patients with BM from non-small-cell lung cancer (NSCLC). However, no study has compared the two treatment modalities. This retrospective analysis was conducted to compare the efficacy of gefitinib alone with gefitinib plus concomitant WBRT in treatment of BM from NSCLC. Methods: We retrospectively reviewed 90 patients with BM from NSCLC who received gefitinib alone (250mg/day, gefitinib group) or with concomitant WBRT (40Gy/20f/4w, gefitinib-WBRT group) between September 2005 and September 2009 at Sun Yat-Sen University Cancer Center. Forty-five patients were in each group. Results: The objective response rate of BM was significantly higher in gefitinib-WBRT group (64.4%) compared with gefitinib group (26.7%, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|